52468-60-7

Basic information

• Product Name: Flunarizine
• Synonyms: (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine;(e)-piperazin;1-[Bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]piperazine;Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (E)-;Sibelium;Fluarizine;1-[Bis(4-fluorophenyl)methyl]-4-[(E)-3-phenyl-2-propenyl]piperazine;FLUNARIZINE
• CAS NO: 52468-60-7
• Molecular Formula: C₂₆H₂₆F₂N₂
• Molecular Weight: 404.49
• EINECS: 257-937-5
• Mol File: 52468-60-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 511.3 °C at 760 mmHg
• Flash Point: 263 °C
• Appearance: /
• Density: 1.17 g/cm³
• Vapor Pressure: 1.43E-10mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: 2-8°C
• PKA: 6.99±0.10(Predicted)
• CAS DataBase Reference: Flunarizine(CAS DataBase Reference)
• NIST Chemistry Reference: Flunarizine(52468-60-7)
• EPA Substance Registry System: Flunarizine(52468-60-7)

Safety Data

• Hazardous Substances Data: 52468-60-7(Hazardous Substances Data)

Usage

Uses

Vasodilator.

Therapeutic Function

Vasodilator

World Health Organization (WHO)

Flunarizine, an antihistaminic and vasodilator agent, was introduced into medicine in 1970. It is indicated for the treatment of central and peripheral vascular disorders. However, its effectiveness in these conditions has not been convincingly demonstrated, and its use has been associated with adverse reactions involving the central nervous system, including extrapyramidal disturbances and depression. This has led several regulatory authorities to restrict the approved indications for products containing flunarizine.

InChI:InChI=1/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2

Upstream product

• 27469-60-9 1-(4-fluorophenyl)methyl-piperazine 
• 4407-36-7 (2E)-3-phenyl-2-propen-1-ol 
• 1522375-87-6 1-(4,4’-difluorophenylmethyl)-4-(2-acetaldehyde)piperazine 
• 1100-88-5 benzyltriphenylphosphonium chloride 
• 1522375-84-3 1-[bis(4-fluorophenyl)methyl]-4-(2,2-dimethoxyethyl)piperazine 
• 369-57-3 benzenediazonium tetrafluoroborate 
• 100-58-3 phenylmagnesium bromide 
• 100-59-4 phenylmagnesium chloride 
• 352-34-1 4-fluoro-1-iodobenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 18903-01-0 trans-1-cinnamylpiperazine 
• 27064-94-4 4,4'-difluorobenzhydryl chloride 
• 18903-01-0 1-(3-phenyl-2-propenyl)piperazine 
• 104-54-1 3-Phenylpropenol 

Relevant articles and documents

Fe-catalyzed synthesis of flunarizine and its (Z)-isomer

-

Ni-Catalyzed Carbon-Carbon Bond-Forming Reductive Amination

This report describes a three-component, Ni-catalyzed reductive coupling that enables the convergent synthesis of tertiary benzhydryl amines, which are challenging to access by traditional reductive amination methodologies. The reaction makes use of iminium ions generated in situ from the condensation of secondary N-trimethylsilyl amines with benzaldehydes, and these species undergo reaction with several distinct classes of organic electrophiles. The synthetic value of this process is demonstrated by a single-step synthesis of antimigraine drug flunarizine (Sibelium) and high yielding derivatization of paroxetine (Paxil) and metoprolol (Lopressor). Mechanistic investigations support a sequential oxidative addition mechanism rather than a pathway proceeding via α-amino radical formation. Accordingly, application of catalytic conditions to an intramolecular reductive coupling is demonstrated for the synthesis of endo- and exocyclic benzhydryl amines.

ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN

The invention generally relates to adenylyl cyclase inhibitor compounds and methods for treating neuropathic or inflammatory pain by using those compounds.